Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.[1]
Business Footprint:[1]The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers.It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Syngene Intl. | 657.05 | 60.53 | 26491.30 | 0.19 | 66.20 | -31.47 | 830.10 | 1.07 | 12.85 | 3454.90 | 26.24 | 437.70 | 66.20 | 5.73 | 7.06 | 0.07 |
| 2. | Indegene | 520.10 | 28.07 | 12512.06 | 0.38 | 102.10 | 11.34 | 804.20 | 17.09 | 24.80 | 3041.00 | 18.91 | 445.80 | 102.10 | 4.36 | 14.19 | 0.04 |
| 3. | Suven Life Scie. | 175.30 | – | 3991.13 | 0.00 | -77.31 | -55.74 | 0.92 | -64.20 | -86.96 | 5.87 | -3637.82 | -211.89 | -77.31 | 14.17 | -78.90 | 0.00 |
| 4. | Vimta Labs | 617.00 | 36.90 | 2754.67 | 0.16 | 19.92 | 17.04 | 101.85 | 20.19 | 25.22 | 383.77 | 34.92 | 74.65 | 19.92 | 6.60 | 15.64 | 0.02 |
| 5. | Fabtech Tech. | 195.59 | 15.89 | 868.93 | 0.00 | 28.11 | 449.02 | 121.48 | 106.81 | 21.98 | 326.67 | 11.87 | 31.69 | 28.11 | – | 9.11 | 0.22 |
| 6. | Take Solutions | 42.87 | 158.87 | 633.88 | 0.00 | 6.29 | 53.33 | 0.00 | – | 11.24 | 0.00 | – | 3.99 | -0.63 | 24.75 | 60.23 | 0.00 |
| 7. | Bilcare | 78.60 | – | 185.06 | 0.00 | -23.32 | -15.39 | 178.20 | -11.67 | 1.10 | 756.72 | 4.30 | -22.15 | -12.36 | 0.41 | -3.53 | 1.48 |
| – | Median: 9 Co. | 175.3 | 48.72 | 868.93 | 0.0 | 6.29 | 11.34 | 101.85 | 12.84 | 11.24 | 326.67 | 8.2 | 3.99 | 0.53 | 5.04 | 7.06 | 0.04 |
Standalone figures in ₹ crores
| Dec 2022 | Dec 2023 | Dec 2024 | Jun 2023 | Jun 2024 | Jun 2025 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 787 | 792 | 877 | 716 | 726 | 799 | 994 | 865 | 948 | 768 | 831 | 821 | 830 |
Expenses | 556 | 592 | 626 | 552 | 578 | 631 | 678 | 565 | 638 | 552 | 614 | 613 | 653 |
Operating Profit | 230 | 200 | 251 | 163 | 148 | 168 | 316 | 299 | 310 | 216 | 217 | 209 | 178 |
Other Income | 17 | 25 | 18 | 23 | 50 | 17 | 23 | 15 | 18 | 15 | 14 | 16 | 14 |
Profit before tax | 139 | 125 | 170 | 92 | 99 | 84 | 241 | 210 | 229 | 129 | 131 | 124 | 84 |
Tax % | 21% | 20% | 28% | 18% | 25% | 12% | 21% | 10% | 24% | 21% | 22% | 22% | 21% |
Net Profit | 110 | 100 | 123 | 75 | 74 | 74 | 189 | 190 | 174 | 102 | 102 | 97 | 66 |
EPS in Rs | 2.73 | 2.48 | 3.06 | 1.87 | 1.84 | 1.84 | 4.71 | 4.72 | 4.33 | 2.53 | 2.53 | 2.40 | 1.64 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 700 | 860 | 1,107 | 1,201 | 1,423 | 1,826 | 2,012 | 2,179 | 2,601 | 3,194 | 3,203 | 3,373 | 3,455 |
Expenses | 485 | 579 | 727 | 816 | 950 | 1,290 | 1,395 | 1,504 | 1,861 | 2,252 | 2,322 | 2,453 | 2,548 |
Operating Profit | 214 | 281 | 380 | 385 | 473 | 536 | 617 | 676 | 741 | 942 | 881 | 920 | 906 |
Other Income | 8 | 12 | 6 | 94 | 53 | 75 | 153 | 94 | 75 | 63 | 74 | 100 | 67 |
Interest | 0 | 8 | 8 | 18 | 23 | 32 | 35 | 28 | 24 | 45 | 30 | 31 | 30 |
Depreciation | 66 | 81 | 97 | 114 | 131 | 164 | 219 | 274 | 310 | 359 | 369 | 367 | 377 |
Profit before tax | 157 | 204 | 281 | 346 | 372 | 414 | 516 | 467 | 482 | 601 | 557 | 622 | 567 |
Net Profit | 135 | 175 | 241 | 287 | 305 | 331 | 412 | 404 | 394 | 473 | 466 | 468 | 438 |
EPS in Rs | 12.45 | 4.38 | 6.02 | 7.18 | 7.63 | 8.27 | 10.29 | 10.09 | 9.83 | 11.78 | 11.60 | 11.63 | 10.87 |
Dividend Payout % | 0% | 239% | 8% | 7% | 7% | 3% | 0% | 0% | 10% | 11% | 11% | 11% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 26 | 199 | 200 | 200 | 200 | 200 | 400 | 400 | 401 | 401 | 402 | 402 | 403 |
Reserves | 633 | 646 | 825 | 1,213 | 1,520 | 1,767 | 1,774 | 2,418 | 2,891 | 3,218 | 3,790 | 4,236 | 4,217 |
Borrowings | 155 | 155 | 891 | 806 | 787 | 813 | 773 | 893 | 1,022 | 639 | 332 | 306 | 312 |
Other Liabilities | 377 | 422 | 440 | 555 | 681 | 922 | 1,215 | 1,166 | 1,247 | 1,590 | 1,310 | 1,462 | 1,172 |
Total Liabilities | 1,191 | 1,422 | 2,356 | 2,775 | 3,188 | 3,702 | 4,162 | 4,878 | 5,561 | 5,848 | 5,834 | 6,407 | 6,104 |
Fixed Assets | 394 | 503 | 580 | 810 | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,260 | 2,318 | 2,241 | 2,515 |
Gross Block | 394.10 | 938.00 | 1,111.40 | 1,331.90 | 1,660.70 | 2,171.00 | 3,017.20 | 3,460.00 | 3,943.50 | 4,070.70 | 4,371.00 | 4,560.90 | – |
Accumulated Depreciation | 0.00 | 434.70 | 531.20 | 521.50 | 630.30 | 794.20 | 997.50 | 1,259.00 | 1,550.70 | 1,810.80 | 2,053.10 | 2,319.70 | – |
CWIP | 45 | 105 | 237 | 175 | 155 | 274 | 234 | 237 | 346 | 126 | 760 | 880 | 550 |
Investments | 352 | 146 | 277 | 540 | 158 | 716 | 777 | 702 | 1,034 | 941 | 928 | 1,468 | 1,367 |
Other Assets | 399 | 667 | 1,262 | 1,249 | 1,845 | 1,336 | 1,132 | 1,737 | 1,787 | 2,521 | 1,829 | 1,818 | 1,673 |
Total Assets | 1,191 | 1,422 | 2,356 | 2,775 | 3,188 | 3,702 | 4,162 | 4,878 | 5,561 | 5,848 | 5,834 | 6,407 | 6,104 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 300 | 18 | 308 | 398 | 446 | 630 | 677 | 698 | 582 | 838 | 913 | 1,114 |
Cash from Investing Activity | -375 | 16 | -753 | -470 | -350 | -646 | -424 | -629 | -611 | -685 | -383 | -810 |
Cash from Financing Activity | 155 | -10 | 716 | -81 | -79 | -72 | -226 | 58 | -31 | -340 | -536 | -136 |
Net Cash Flow | 80 | 24 | 272 | -153 | 17 | -88 | 28 | 127 | -60 | -187 | -6 | 167 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 49 | 76 | 61 | 60 | 68 | 68 | 72 | 79 | 71 | 55 | 49 | 51 |
Inventory Days | 28 | 59 | 44 | 37 | 82 | 30 | 18 | 41 | 87 | 141 | 95 | 62 |
Days Payable | 146 | 106 | 87 | 116 | 194 | 154 | 157 | 166 | 115 | 110 | 104 | 143 |
Cash Conversion Cycle | -68 | 29 | 18 | -19 | -44 | -56 | -67 | -45 | 44 | 86 | 41 | -30 |
Working Capital Days | -142 | -64 | -65 | -44 | -48 | -103 | -172 | -65 | -43 | 21 | -30 | -59 |
ROCE % | 23% | 23% | 20% | 18% | 16% | 17% | 17% | 14% | 13% | 15% | 13% | 13% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2025
Sep 2025
Jul 2025
Apr 2025
Mar 2025
Jan 2025
Oct 2024
Jul 2024
Jul 2024
Apr 2024
Jan 2024
Jan 2024
Oct 2023
Jul 2023
May 2023
Jan 2023
Oct 2022
Jul 2022
Apr 2022
Jan 2022
Oct 2021
Jul 2021
Apr 2021
Mar 2021
Jan 2021
Oct 2020
Jul 2020
May 2020
Feb 2020
Jan 2020
Dec 2019
Oct 2019
Jul 2019
Apr 2019
Feb 2019
Oct 2018
Jul 2018
May 2018
Apr 2018
Jan 2018
Nov 2017
Aug 2017
May 2017
Jan 2017
Oct 2016
Jul 2016
Feb 2016
Oct 2015
Stock Analysis
Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Its team of over 8,200 employees, including 5,600 scientists, provides deep expertise and capacity for scientific excellence, robust data security, and world-class manufacturing.
Currently no data available for Key Growth Triggers.
Currently no data available for Order Book.
Currently no data available for Key Red Flags.
Corporate Announcements
